Atovaquone for Treatment of COVID-19
Phase: PHASE2
Conditions: COVID-19
Sponsor: University of Texas Southwestern Medical Center

 
 
 
Atovaquone for the Treatment of COVID-19: ATaQ 
 
NCT04456153 
 
Protocol version 2 Approved August 19,2020 
 
Statistical Analysis Plan updated 2.16.21 
 
 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
Atovaquone for Treatment of COVID-19 
Ataq COVID-19 
 
Study Design: This is a randomized, double-blind study of atovaquone therapy in adult 
participants hospitalized with COVID-19. Approximately 60 participants who meet all 
eligibility criteria may be randomized in a 2:1 atovaquone/placebo ratio into one of the 
following treatment groups:  
Treatment Group 1: continued standard of care therapy together with an oral dose of 
1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days 
Treatment Group 2: continued standard of care therapy together with matching placebo 
Primary Efficacy Endpoint: Viral load (Log copy number/ml by RT-PCR) from saliva 
collection at Day 8 from trial entry, or at hospital discharge (if discharged before Day 8).   
Secondary Efficacy Endpoints:  
 
1. Change in viral load (Log copy number/ml) from baseline to Day 8 (or to 
discharge if discharged before day 8). 
2. Viral load (log copy number/ml by RT/PCR) from saliva collection at Day 15 or 
hospital discharge if discharged prior to Day 15. 
3. Days from baseline to decrease in viral load by ≥2 Log copy number/ml. 
4. Proportion with viral clearance (undetectable by RT-PCR) by last day of 
hospitalization or Day 8 of trial. 
5. Proportion with viral clearance (undetectable by RT-PCR) by last day of 
hospitalization or Day 15 of trial.  
6. Proportion with ≥2 Log copy number/ml change by Day 8 or by discharge from 
hospital if discharged before Day 8. 
7. Proportion with ≥2 Log copy number/ml change by Day 15 or by discharge from 
hospital if discharged before Day 15. 
8. Days to viral clearance among those with viral clearance (undetectable by RT-
PCR) on last day of hospitalization or Day 8 if still hospitalized. 
9. Days to viral clearance among those with viral clearance (undetectable by RT-
PCR) on the last day of hospitalization of Day 15 if still hospitalized. 
10. Exploratory clinical endpoint: Time to clinical improvement of ≥2 points on the 
ordinal clinical scale or discharge alive, whichever comes first 
11. Exploratory endpoint: Change in routinely collected clinical biomarkers such as 
CRP, ferritin, D-Dimer, IL-6 hs-cTnT and NT-proBNP among those randomized 
to treatment vs. placebo from baseline through day 8. 
 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
For all analyses of viral load and clearance, results from salvia samples will be used for 
primary and secondary analyses. If salvia cannot be obtained (i.e due to mechanical 
ventilation), a nasopharyngeal swab can be used. 
 
Ordinal Clinical Scale 
The ordinal scale is an assessment of the clinical status at the first assessment of a given 
study day.  Obtain Day 8 Ordinal scale   
1. Death 
2. Hospitalized, on invasive mechanical ventilation or ECMO 
3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 
4. Hospitalized, requiring supplemental oxygen 
5. Hospitalized, not requiring supplemental oxygen 
6. Discharged 
 
Safety Endpoint: Between group difference in treatment-emergent adverse 
events leading to study drug dose reduction or discontinuation.  
 
Statistical Methods:  
All analyses will be performed among randomized participants who received at least one 
dose of study drug and has at least one post-baseline viral load measurement.  
 
1. Given the skewed distribution of the viral load measurement, viral load will be 
compared at Day 8 and end of hospitalization  among those who are discharged prior 
to Day 8 between groups with the Wilcoxon rank-sum test.  
2. Differences between baseline and day 8 or last day of hospitalization if discharged 
prior to Day 8 viral load will be compared between groups with the Wilcoxon rank-sum 
test. Within group differences will be assessed via the Wilcoxon signed-rank test.   
3. Days from baseline to decrease in viral load by 2 log copy number/ml will be 
determined using  Kaplan-Meier analysis,  and the treatment groups will be compared 
with the log-rank test. The median number of days from baseline to the decrease in 
viral load will be compared via the Wilcoxon rank-sum test. 
4. Proportions with viral clearance ≥ 2 log copy number change/mL at  Day 8 or last day 
of hospitalization if discharged prior to Day 8 will be compared between groups with 
the Chi square test.   
5. Days to clinical improvement ≥2 points on the ordinal scale or discharged alive, 
whichever comes first, will be determined using  Kaplan-Meier analysis, and the 
treatment groups will be compared with the log-rank test. The change in ordinal score 
will be compared between groups via the Wilcoxon rank-sum test. 
There is no methodological approach for handling missing data values that is universally 
accepted in all situations. However, we propose to use an iterative Markov chain Monte 
Carlo method that can be used when the pattern of missing data is monotone (i.e. a 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
patient attends all visits until a visit is missed and never returns) or non-monotone. Last 
observation carried forward (LOCF) is generally considered as a conservative approach, 
but the MCMC simulation method we propose will reduce the risk of overestimation of the 
precision of the treatment effect.  
Sample Size and Statistical Power: 
A total of 60 participants will be randomized in a 2:1 ratio to 2 groups (Approximately 40 
participants in atovaquone group and 20 in placebo group) This sample size would result 
in the following statistical power for the viral clearance endpoints 
1. For the endpoint of viral load (log copy number/ml) at  Day 8 and last day of 
hospitalization 1, assuming a mean difference between the groups of 1.6 log copy 
number/mL, with equal standard deviations of 2, the power will be 82%  
2. For the endpoints of differences between baseline and Day 8 or last day of 
hospitalization viral load, assuming, a mean difference-in-difference of >2.5 with a 
common SD of 3, the power will be >80% 
3. For the endpoint of days from baseline to decrease in virial load by ≥2 log copy 
number/ml, the power will be >90% assuming a difference of 2 days between the 
treatment groups with a standard deviation of 1 day. 
4. For the analyses of the proportions with viral clearance, and the proportion with ≥2 log 
copy number change at Day 8, the study will have > 80% power to detect a 40% 
absolute difference between groups and 62% power to detect a 30% difference 
between groups.   
5. Because the ordinal scale and biomarker comparisons are exploratory, no power 
calculations are provided 
Aggregate blinded viral load data will be reviewed during the study and if the magnitude 
and/or rate of viral clearance is lower than estimated, or the standard deviation is higher, 
consideration will be given to increase the sample size accordingly. 
Interim Analysis:  
 The Data Safety and Monitoring Board (DSMB) will meet to evaluate data when 50% of 
enrolled patients have completed 10 days. The DSMB will review number of deaths, 
number of those on ventilators, and grade 3 and 4 drug related toxicities.  
Background 
In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, 
Hubei, China. Sequencing analysis from the patients’ respiratory tract samples indicated 
a novel coronavirus (CoV), which was named COVID-19. As of April 21 2020, more than 
9 million confirmed cases have been identified globally. More than 400,000 deaths 
associated with COVID-19 have been reported, making COVID-19 and major health 
emergency. On March 11, World Health Organization (WHO) declared the resulting 
disease named COVID-19 as a pandemic2. Clinical efforts to discover potential vaccines 
and therapeutics are still ongoing with no clear treatment or prophylaxis for COVID-19 in 
sight. It is safe to say that a sufficient understanding of SARSCoV-2, and the full clinical 
picture of the resulting COVID-19 disease will take some time. Similarly, developing and 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
widely distributing effective vaccines or novel antiviral drugs is unlikely to occur during 
this season, which leaves healthcare systems vulnerable, and risks high mortality rates. 
Alternatively, drug repurposing strategies can create viable pathways towards 
identification of potential therapeutics with established safety profiles that can be used 
individually or in combinations for targeting molecular regulators of replication or the 
survival of SARS-CoV-2. While these strategies are unlikely to provide immunity or cure, 
they may identify therapeutics that can alter the clinical course of COVID-19 3-8. 
The betacoronavirus genome encodes structural proteins, including the glycosylated 
spike (S) protein that serves as a major inducer of host immune responses. The spike 
protein mediates host cell invasion via binding to angiotensin converting enzyme 2 
(ACE2) (a homolog of angiotensin converting enzyme ACE) which is a membrane bound 
carboxypeptidase). The cellular invasion process appears to be mediated by priming of 
the S protein facilitated by the host cell-produced serine protease TMPRSS2. In addition, 
the viral genome also encodes nonstructural proteins including RNA-dependent RNA 
polymerase (RdRp), coronavirus main protease (Mpro), and papain-like protease (PLpro) 
5,9,10.  
Therefore, targeting ACE2, TMPRSS211, RdRp, Mpro, and PLpro, as individual targets, 
or in combination, is a viable strategy for repurposed drugs. To that end, different drug 
repurposing efforts have been executed starting with data driven framework coupled with 
in vitro assays. One study demonstrated the potential of a poly-ADPribose polymerase 1 
(PARP1) inhibitor, CVL218, currently in a Phase I clinical trial, that may serve as a 
potential drug candidate to inhibit SARS-CoV-2 replication in a dose-dependent manner 
and with no obvious cytopathic effect. CVL218 showed potential binding affinity of the N-
terminal domain of nucleocapsid (N) protein of COVID-19 virus via in-silico analysis11.  
We adopted a repositioning approach using in-silico molecular modeling to screen FDA 
approved drugs with established safety profiles for potential inhibitory effects on COVID-
19 virus. Starting with the published crystal structure provided us with structural insights 
for the catalytic binding domain and active druggable sites, while concurrently elucidating 
free binding energies with respect to binding affinity and interactions. Our structure-based 
approach for drug screening was focused on targeting COVID-19 virus Mpro based on the 
elegant work that resulted in solving the crystal structure of COVID-19 Mpro in complex 
with an inhibitory peptide N3 (PDB ID:6LU7). In particular, that inhibitory peptide binds 
the substrate-binding pocket of COVID-19 Mpro. This domain was the focus of our screen 
with regards to the potential hydrophobic binding domain and considering the hydrogen 
bond network. 
We started with structure-based drug screening of more than 2000 FDA approved drugs 
against COVID-19 virus main Mpro substrate-binding pocket focusing on two potential 
sites (central and terminal sites) to identify potential hits based on their binding energies, 
binding modes, interacting amino acids, and therapeutic indications. In addition, we 
screened the top hits at both binding sites for potential covalent binding via nucleophilic 
thiol attack of Cys 145. We also elucidated the preliminary pharmacophore features for 
the top candidates using the three strategies bound to COVID-19 virus Mpro substrate-
binding pocket. Finally, we performed in vitro viral replication assays on a number of the 
top hits in Vero cells to confirm antiviral activity.  

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
 
The top hits that bound to the central site of the Mpro substrate-binding pocket included 
anti-viral drugs such as darunavir, nelfinavir and saquinavir (some of which are already 
being tested in COVID-19 patients,) as well as the hypercholesterolemia drug 
rosuvastatin and the anti-malarial drug atovaquone. The top hits that bound to the 
terminal site of the Mpro substrate-binding pocket include the anti-asthma drug 
montelukast and the anti-histamine drug fexofenadine, among others. Finally, the top 
candidates predicted to undergo covalent binding were atovaqoune, mitoxantrone, and 
metamizole.  
 
We performed viral replication assays on all top hits from our in silico screen. The only 4 
drugs that inhibited viral replication out of the top hits using the 3 docking strategies were all 
predicted to bind covalently to Cys145. These drugs are Atovaquone, Ouabain, Dronedarone, 
and Mebendazole. We determined the following IC50s in Vero E6 cells: Atovaquone (1.5 M); 
Ouabain (0.030 M); Mebendazole (0.25-1.2 M) and Dronedarone (1.5 M– however 
dronedarone antiviral was likely secondary to cell toxicity). Drondarone had significant cellular 
toxicity, while ouabain is no longer approved in the US and mebendazole in not marketed in the 
US any longer. Therefore, the top hit from our screen than can be immediately repurposed for 
treatment of COVID-19 patients is atovaquone.  
 
  
Atovaquone: 
Investigations into the treatment for COVID-19 span different mechanisms, as no 
consensus has been reached on what is the main driver of pneumonia, respiratory failure 
and systemic complications. One approach is antiviral in which the investigational drug 
would clear viral infection leading to improvement in clinical outcome; an alternative 
approach is anti-inflammatory in which the investigational drug would reduce levels of 
inflammatory cytokines to improve clinical outcomes. Yet, other mechanisms are being 
targeted to treat systemic complications of COVID-19 such as anti-thrombotics to prevent 
and treat associated venous and arterial thromboses. Which mechanism is the main 
driver of clinical morbidity and mortality is unknown. Currently the most promising of the 
antiviral therapies under investigation, remdesivir, requires IV administration, is only 
available in the setting of a clinical trial or by eIND mechanism for compassionate use, 
and cannot be used in those with severe kidney disease. The oral anti-malaria drugs 
hydroxychloroquine and chloroquine are being evaluated for COVID-19 treatment and 
also prophylaxis, but concerns have been raised because of toxicities, most notably that 
both drugs prolong the QT interval with reported cases of Torsades de Pointes associated 
with each.   
In the present study, we chose to focus on the antiviral approach. We seek to evaluate 
atovaquone to (1) determine antiviral activity (2) to explore if viral reduction or clearance, 
if achieved, is associated with improvement in clinical outcome.  
Atovaquone is an oral solution used as treatment of pneumocystis jirovecii pneumonia 
(PJP), for those unable to receive or tolerate trimethoprim-sulfamethoxazole, at a dose of 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
750 mg twice a day for 21 days. Atovaquone is also used for prophylaxis against PJP at 
a dose of 1500 mg daily. Other labeled indications include: toxoplasmosis treatment and 
babesiosis treatment, at doses up to 3000mg daily in 2-4 divided doses. 
Mechanism of action and spectrum of activity : Atovaquone is a competitive inhibitor of 
ubiquinol and specifically inhibits the mitochondrial electron transport chain at the bc1 
complex12. Atovoquone is broad-spectrum and is used to treat malaria with an IC50 against 
malaria in vitro of 1-3.5nM. However, it has high levels of plasma protein binding 
substantially decreasing levels of unbound atovaquone12. Atovaquone has also been 
found to inhibit arboviruses such as Zika and chikungunya virus  replication by depletion 
of  intracellular nucleotides13. Additionally, atovaquone has been shown to reduce the 
interleukin-6/STAT3 signaling pathway in myeloma cells and in acute myeloid leukemia14. 
Drug concentration:  
Molecular weight: 366.837 g/mol 
MEPRON Suspension has been administered at dosage regimens of 500 mg once daily, 
750 mg once daily, and 1,000 mg once daily to deduce Cmax concentrations at 15.1 ± 6.1 
(40.89 µM), 15.3 ± 7.6 (41.7 µM), and 16.8 ± 6.4 µg/mL (45.79 µM), respectively. 
In the treatment of PJP, average (Cavg/ss) plasma concentrations of 10 to <15 g/mL and 
15 to <20g/mL yielded 79% to 95% success in treatment. The bioavailability of 
atovaquone is variable as determined in 6 clinical trials in HIV patients when used for the 
treatment of PJP. This is likely to due to solubility and the effect of food on GI absorption. 
In a study of 33 patients with either HIV or hematological malignancy requiring 
atovaquone, patients were dosed 750 mg twice a day and Cmin was obtained 12 hours 
after evening dose and Cmax 1-5 hours after morning dose. The median Cmin (IQR) was 
11.3 g/ml (6.2-27.8) and median Cmax (IQR) was 13.4 g/mL (6.0-28.3) and were not 
different between HIV and non-HIV patients. Nineteen of 33 (58%) had Cmin <15g/mL 
which may impact clinical response for PJP.  
Metabolism: Under normal conditions, there is no evidence that atovaquone is 
significantly metabolized in humans, or that metabolism is required for drug elimination. 
It may be possible that certain enzymes could be induced and therefore lead to increased 
atovaquone biotransformation, but this has not been demonstrated 15. 
Elimination: The pharmacokinetic half-life of atovaquone was 62.5 ± 35.3 hours after IV 
administration and ranges from 67.0 ± 33.4 to 77.6 ± 23.1 hours across studies following 
administration of MEPRON Suspension. Atovaquone pharmacokinetics are characterized 
by an extremely long elimination half-life of 50–84 h after oral administration of 250 mg 
16.  

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
Distribution: Atovaquone is extensively bound to plasma proteins (99.9%) and therefore 
the concentration of unbound atovaquone in the vascular compartment will be 
significantly lower than measured plasma concentrations17. In a study of atovaquone 
population pharmacokinetics, the volume of distribution of atovaquone was 7.98 L/kg, 
although individual values were markedly linked to body weight; the volume of distribution 
shows a linear increase with increased patient body weight18. This volume of distribution 
indicates that atovaquone is not confined to the intravascular space.  
We were unable to find literature describing the tissue concentration of atovaquone 
following systemic administration, however, several reports suggest that atovaquone is 
not confined to the intravascular space, despite being highly bound to albumin given that 
it has a low drug clearance rate, which suggests that it likely accumulates in tissue12 
Another level of evidence in support of tissue accumulation of atovaquone is the effective 
concentration needed for its therapeutic effect. While the IC50 for atovaquone against 
falciparum malaria is in the low nanomolar range, the IC50 for atovaquone for 
pneumocystis jirovecii pneumonia is from 0.1-3.0 ug/ml, which is equivalent to 8.178 
M.  
The IC50 for atovaquone against SARS-CoV-2 in our assay is approximately 800 nM, 
which is well within the therapeutic range as outlined above. Therefore, we predict 
that the inhibitory effect on SARS-CoV-2 is well within the FDA approved dosing 
regimen.  
Drug interaction: Atovaquone exposure is markedly decreased when taken with rifampin.  
Tolerability: Atovaquone has been found to be generally well tolerated.  Adverse events 
have been mild and include rash, fever, diarrhea, abdominal pain, and headache.  
Current studies in COVID-19: Currently, an independent single center, single arm open-
label trial is underway examining atovaquone 750 mg bid for up to 10 days in combination 
with azithromycin 500mg X 1 followed by 250mg daily for up to 10 days for COVID-19. 
[NCT04339426] However, this study is limited by evaluation of atovaquone only in 
combination with azithromycin and by the absence of a contemporary control group for 
comparison.  
 
Design of the ATaQ COVID-19 Trial 
The purpose of the current study is to accelerate the use of a clinically available 
therapeutic already FDA-approved for other indications in the setting of pandemic COVID-
19 addressing a serious and emergent unmet medical need. In consideration of the 
information included in this protocol, the overall risks to participants are outweighed by 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
the potential benefits of atovaquone experimental therapy for the treatment of COVID-19. 
The benefit-risk balance for this study is considered positive. 
Inclusion Criteria: 
1. 
Diagnosis of COVID-19 by positive RT-PCR requiring hospitalization within 72 
hours 
2. 
Age ≥18 years old 
3. 
Able to provide informed consent, or (as allowed by IRB), immediate availability of 
designated legally authorized representative to provide consent by proxy 
4. 
Anticipated hospitalization for >48 hours  
 
Exclusion Criteria 
Patients who meet any of the following exclusion criteria are not to be enrolled in this 
study: 
1) Participation in any other clinical trial with antiviral activity against COVID-19  
2) Breastfeeding women 
3) Known hypersensitivity to atovaquone or formulation excipient 
4) Active treatment with rifampin 
5) HIV patients with AIDS requiring treatment for Pneumocystis jirovecii or Toxoplasma 
gondii  
6) Not expected to survive for 72 hours.  
7) >14 days from symptom onset  
Randomization 
Patients who meet eligibility criteria and volunteer to participate will be randomized in a 
2:1 ratio to atovaquone or placebo on Day 1 using computerized randomization. An 
unblinded investigational pharmacist not otherwise involved in the trial will know treatment 
assignment and dispense investigational product. As GI absorption of atovaquone 
increased when taken with food, so we will administer with a meal or snack.  
Blinding 
Double blinding of treatment assignments will be performed in this study, with the study 
team and patients blinded to treatment assignment. 
The list of concomitant medications will be assessed only from Day 1 prior to enrollment 
to Day 15 or discharge, whichever is earlier.  
Patient Enrollment and Treatment Assignment 
Entry into screening does not guarantee enrollment into the study. In order to manage the 
total study enrollment, the study researchers may suspend screening and/or enrollment 
at any at any time. 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
Pretreatment Assessments 
Screening Visit 
Patients will be screened within 2 days before randomization and dosing to determine 
eligibility for participation in the study. Screening will occur under approved HIPAA waiver 
for research to identify and screen all hospitalized COVID-19 positive patients on a daily 
basis. 
Obtain informed consent. 
After informed consent has been negotiated and the form signed, the following 
assessments will be performed to determine eligibility requirements as specified in the 
inclusion and exclusion criteria: 
• Review of focused medical history including the following information (e.g., date of 
first symptoms, overall symptoms, exposure source, demographics, baseline 
characteristics), allergies and past medical history. 
• Review and record medications and therapies for the current illness 
• Recording of vital signs (heart rate, temperature, blood pressure), body weight, 
and height 
• Documentation of respiratory support: Respiratory Rate, Oxygen supplementation: 
room air, nasal canula, face mask, non-rebreather, high-flow device, mechanical 
ventilation; and FiO2 
• SpO2 at rest or PaO2 
• Radiographic findings 
  
Study patients who qualify and volunteer to participate should be immediately consented 
and randomized. Randomization and initiation of dosing should occur on the same day if 
possible. 
Baseline/Day 1 Assessments 
The following evaluations are to be completed at the Day 1 visit. The investigator must 
have confirmed eligibility and signing of consent before proceeding with randomization 
on the Day 1 visit, followed immediately by first dose of investigational product. The 
assessments can be completed by the patient care team and do not need to be repeated 
by research personnel. The following assessments must be documented before 
administering investigational product, using the most recent data available at the time of 
randomization: 
Recording of vital signs (heart rate, temperature, blood pressure, body weight, height) 
Documentation of respiratory status: 
Respiratory rate 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
Oxygen supplementation and FiO2: room air, nasal canula, face mask, non-rebreather, 
noninvasive ventilation or high flow oxygen devices, mechanical ventilation, or ECMO  
Oxygenation: (SpO2 or PaO2) 
Radiographic findings (if available) 
Review AEs and document concomitant medications 
Document Ordinal Scale at baseline 
Obtain saliva sample and nasopharyngeal swab sample for viral load quantification at day 
1 prior to initial dose  
Obtain blood for research sample 
Daily Study Assessments (Days 2-10) 
The following evaluations are to be documented daily from Days 2 – 10 or until discharge 
whichever comes earlier, using the data recorded at or closest to 12:00 noon each day: 
• Vital signs (heart rate, temperature, blood pressure), body weight (if available). 
• Documentation of respiratory status: Respiratory rate, Oxygen supplementation 
and FiO2: room air, nasal canula, face mask, non-rebreather, noninvasive 
ventilation or high flow oxygen devices, mechanical ventilation, or ECMO  
• Oxygenation: (SpO2 or PaO2) 
• Radiographic findings (if available) 
• Review of AEs and document concomitant medications  
• 
Saliva sample for COVID-19 RT-PCR every 12 hours  (Days 2-8) 
• Saliva sample for COVID-19 RT-PCR once daily (Days 9-10)  
• Additional blood draws  for biobanking (Day 3, and 5 only ) 
• A patient who does not have 5 saliva samples collected prior to discharge, the 
patient may be given saliva kits for home collection if deemed that patient can 
follow instructions and collect saliva correctly.  
Clinical Laboratory Assessments 
Clinical laboratory assessments will be conducted as clinically indicated and all laboratory 
testing will be completed by local laboratories. Clinical laboratory data to be captured in 
the trial database will include serum chemistries, liver function tests, complete blood 
counts including absolute neutrophil count, CRP, hs-CRP, D-dimer, ferritin, IL-6, troponin, 
NTpBNP.  
SARS-CoV-2 testing will include RT-qPCR to detect or quantify SARS-CoV-2 or virus 
sequencing results from saliva (baseline and daily until discharge or death, and 8 days 
and last day of hospitalization or Day 15 if still hospitalized. 
Pretreatment and posttreatment samples with detectable SARS-CoV-2 may be 
sequenced for resistance monitoring of the viral polymerase gene. For all clinical 
laboratory tests, except those at Day 1, when more than 1 result is available in a calendar 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
day, the value closest to 12:00 noon should be captured in the eCRF. For Day 1 tests, 
the most recent result before dosing should be used. 
Physical Examination 
No physical examination is mandated by the study protocol beyond the capture of vital 
signs (heart rate, respiratory rate, temperature, blood pressure, SpO2 at rest or PaO2) as 
documented clinically.  
Post-treatment Assessments 
Treatment will continue to complete a 10 Day course or until viral clearance is 
documented, whichever occurs first.  
Telephone call on Day 15 and 29  for those discharged. The phone call  will include a 
brief survey on symptoms and  information on any re-hospitalizations.  
Final review of AEs and concomitant medication 
Vital signs will be captured if still inpatient and the ordinal scale will be assessed. 
Assessments for Early Discontinuation from Study 
If a patient discontinues study dosing (for example, as a result of an AE, intolerance of 
investigational product, or clinically significant laboratory abnormality felt to be at least 
possibly trial-related), every attempt should be made to keep the patient in the study and 
continue to perform the required study-related follow-up and procedures. If this is not 
possible or acceptable to the patient or investigator, the patient may be discontinued from 
the trial, with phone call for vital status on trial Day 29. 
Drug Dosage Reduction:  
Atovaquone should be given with food to increase absorption and to possibly limit GI 
intolerance. Known adverse events including nausea, vomiting and diarrhea. If patient 
develops moderate to severe GI symptoms, a reduction in dose to 750 mg bid can be 
instituted per investigator discretion to enhance the likelihood for the patient to complete 
therapy.  
Criteria for Discontinuation of Study Treatment 
Study medication may be interrupted or discontinued in the following instances: 
 
• Intercurrent illness that would, in the judgment of the investigator, affect 
assessments of clinical status to a significant degree. Following resolution of 
intercurrent illness, the patient may resume study dosing at the discretion of the 
investigator. 
• Unacceptable toxicity, or toxicity that, in the judgment of the investigator, 
compromises the ability to continue study-specific procedures or is considered to 
not be in the patient’s best interest 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
• Patient request to discontinue for any reason 
• Discontinuation of the study at the request of a regulatory agency or an institutional 
review board (IRB) 
• DSMB recommends termination of trial 
• Patient may be  able to receive other treatments for COVID-19 at the discretion of 
the treating providers if there is disease progression or after completion of 10 days 
of treatment. Study medication does not need to be stopped when additional 
medication is started.  
 
End of Study 
The end of the study will occur when the last participant’s last observation (or visit). 
Post Study Care 
The long-term care of the participant will remain the responsibility of their primary treating 
provider. Atovaquone is being supplied with curative intent. There is no provision for post-
study availability. 
 
 
 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
References: 
1. 
Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients 
infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: 
retrospective cohort study. BMJ. 2020;369:m1443. 
2. 
Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current 
scenario, evolutionary perspective based on genome analysis and recent 
developments. Vet Q. 2020;40(1):68-76. 
3. 
Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target 
for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226-236. 
4. 
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the 
prefusion conformation. Science. 2020;367(6483):1260-1263. 
5. 
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on 
ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 
2020. 
6. 
Anthony SJ, Johnson CK, Greig DJ, et al. Global patterns in coronavirus diversity. 
Virus Evol. 2017;3(1):vex012. 
7. 
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main 
proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 
2003;300(5626):1763-1767. 
8. 
Wang F, Chen C, Tan W, Yang K, Yang H. Structure of Main Protease from Human 
Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci 
Rep. 2016;6:22677. 
9. 
Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. Nidovirales: evolving the largest 
RNA virus genome. Virus Res. 2006;117(1):17-37. 
10. 
Baez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like 
protease: structure, function and inhibition by designed antiviral compounds. 
Antiviral Res. 2015;115:21-38. 
11. 
Chang KO, Kim Y, Lovell S, Rathnayake AD, Groutas WC. Antiviral Drug Discovery: 
Norovirus Proteases and Development of Inhibitors. Viruses. 2019;11(2). 
12. 
Nixon GL, Moss DM, Shone AE, et al. Antimalarial pharmacology and therapeutics of 
atovaquone. J Antimicrob Chemother. 2013;68(5):977-985. 
13. 
Cifuentes Kottkamp A, De Jesus E, Grande R, et al. Atovaquone Inhibits Arbovirus 
Replication through the Depletion of Intracellular Nucleotides. J Virol. 2019;93(11). 
14. 
Stevens AM, Xiang M, Heppler LN, et al. Atovaquone is active against AML by 
upregulating the integrated stress pathway and suppressing oxidative 
phosphorylation. Blood Adv. 2019;3(24):4215-4227. 
15. 
Nixon GL, Moss DM, Shone AE, et al. Antimalarial pharmacology and therapeutics of 
atovaquone. Journal of Antimicrobial Chemotherapy. 2013;68(5):977-985. 
16. 
Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state 
pharmacokinetics of a novel microfluidized suspension of atovaquone in human 
immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother. 
1996;40(3):556-560. 
17. 
Zsila F, Fitos I. Combination of chiroptical, absorption and fluorescence 
spectroscopic methods reveals multiple, hydrophobicity-driven human serum 
albumin binding of the antimalarial atovaquone and related 
hydroxynaphthoquinone compounds. Org Biomol Chem. 2010;8(21):4905-4914. 

 
STU2020-0707, Jain, FormA-ResearchProtocol-V2, Mod_3, 08-10-20 
 
Protocol version 2  August 2, 2020 
 
18. 
Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of 
atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin 
Pharmacol Ther. 1997;61(5):518-530. 
 

February 10, 2021 
 
 
 
ATAQ Trial Statistical Analysis Plan 
 
Prospectively will omit any sample with no detectable GADPH housekeeping and any with GADPH Ct >34  
Values below detection limit will be assigned a value ½ between lowest detection limit and zero 
All analyses will be intention-to-treat 
 
Primary analysis: Between group differences in viral load (Log copy number/ml) using generalized linear 
mixed-effect models of repeated measures (GLMM), using data from all samples 
Secondary/exploratory analyses: 
1. Between group differences in viral load (Log copy number/ml) using GLMM, assessing 
differences at at 3, 5, and 7 days 
2. AUC comparison between groups of viral load (Log copy number/ml) through day 3 and day 7 
via the trapezoidal rule. 
3. Between group differences in viral load (Log copy number/ml) using  GLMM  stratified by 
a. Morning (a) and evening (b) samples 
b. By any remdesivir use 
c. By any monoclonal or polyclonal antibody use 
d. By median split of baseline values 
e. By median split time from onset of symptoms 
f. By median split of BMI 
g. By DM status 
h. Sex 
i. 
Age 
4. Between group comparison of time to drop in viral load (Log copy number/ml) of 2 log units 
using Kaplan-Meier estimation 
5. Change of ≥2 points on the ordinal scale at Day 5 by chi-square analysis